Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.
This phase 2a trial demonstrates that monlunabant induces significant weight loss across various doses in obese adults with metabolic syndrome, with dose-dependent adverse events highlighting the need for further safety evaluation.
This study compares long-acting injectable to oral antipsychotics in older schizophrenia patients, highlighting benefits in relapse prevention and mortality reduction, with specific considerations for adverse effects.
This study quantifies how specific resistance genes influence minimum inhibitory concentrations in E. coli, enhancing prediction accuracy for antibiotic resistance.
Artificial intelligence is reshaping health care, offering vast potential benefits alongside significant challenges. The JAMA Summit emphasizes the need for robust evaluation, equitable deployment, and multi-stakeholder collaboration to ens
This systematic review evaluates lithium’s efficacy in reducing suicidal ideation, attempts, and completed suicide, highlighting methodological challenges and the likelihood of benefit despite lack of statistical significance in RCTs.
This meta-analysis examines Coenzyme Q10 supplementation’s impact on depression and anxiety, revealing modest benefits for depression at low doses and short durations but insufficient evidence for anxiety improvement.
This comprehensive meta-analysis quantifies the efficacy of five major antihypertensive drug classes and their combinations, providing clinicians with evidence-based guidance on blood pressure-lowering intensity to optimize hypertension tre
A nurse-driven, patient-centered education bundle significantly reduced missed doses of venous thromboembolism prophylaxis in a community hospital, demonstrating scalable improvements in prophylaxis adherence beyond academic centers.
The EASI trial compared a once-daily 1600 mg 5-ASA tablet with the conventional three 800 mg tablet regimen for ulcerative colitis, finding similar adherence and relapse rates, suggesting a feasible simpler alternative.
This meta-analysis reveals that short-term mortality in severe alcohol-associated hepatitis remains high, with no significant improvement over the past four decades despite advances in care, underscoring the urgent need for better therapies
In primary biliary cholangitis (PBC) patients treated with obeticholic acid (OCA), biochemical non-response strongly predicts a higher risk of clinical events including liver decompensation and mortality, underscoring the need for improved
Altered gut microbiota composition and metabolism exacerbate cirrhotic portal hypertension, highlighting potential microbiome-targeted therapies to mitigate disease progression.
Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorr
The 2025 Nobel Prize in Physiology or Medicine honors groundbreaking work on regulatory T cells, revealing how the immune system avoids self-attack while combating threats, paving the way for novel therapies in autoimmune and transplant med
Many US adults who consume alcohol support policies like cancer warnings and advertising restrictions on alcohol, with demographic variations in support levels.
This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.
A recent trial comparing adaptive, algorithm-driven telephone support with static monthly coaching found no significant difference in long-term weight loss maintenance, highlighting complexities in obesity treatment and the need for refined
Open language-specific specialty feeds and department pages.